Literature DB >> 17229225

Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.

P B Miner1, L D Allgood, J M Grender.   

Abstract

BACKGROUND: The onset of acid inhibition for proton pump inhibitors is slower than with H2RAs and generally considered to be at a steady-state after 5 days. Thus, little direct comparison data exists between H2RAs and proton pump inhibitors for gastric acid suppression on day 1 of therapy. Furthermore, the durability of their acid suppression has not been systematically compared. AIM: To compare the effects of 20.6 mg omeprazole magnesium o.m. (Ome-Mg 20), famotidine 10 mg b.d. (Fam 10) and famotidine 20 mg b.d. (Fam 20) on intragastric pH on day 1 and throughout 14 days of dosing.
METHODS: The study was a randomized, double-blind, three-dosing regimens, three-period crossover. Healthy adults with frequent heartburn (> or =2 days/week) underwent 24-h gastric pH monitoring on days 0 (baseline), 1, 3, 7 and 14.
RESULTS: Thirty-one subjects were included in the per-protocol analyses. On day 1, the mean percentage time pH > 4 (pH4%) was higher for Ome-Mg 20, 44.6%, than for Fam 10, 36.7% (P = 0.032), and not different from Fam 20, 46.9% (P = 0.541). The pH4% was higher for Ome-Mg 20 than either famotidine regimen on all subsequent monitoring days (P < 0.001). The 24-h area under the mean intragastric pH curve showed a similar pattern. Furthermore, after day 1, Ome-Mg 20 demonstrated an increasing and sustained effect in contrast to a decreasing effect for famotidine, consistent with H2RA tolerance.
CONCLUSION: Gastric acid suppression on Ome-Mg 20 mg o.m. over 14 days was comparable with Fam 10 mg b.d. or Fam 20 mg b.d. on day 1, and superior thereafter.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17229225     DOI: 10.1111/j.1365-2036.2006.03129.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

Review 1.  Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing.

Authors:  Johnson W McRorie; James A Kirby; Philip B Miner
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

2.  Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD.

Authors:  Gerald Holtmann; Marc-André Bigard; Peter Malfertheiner; Roy Pounder
Journal:  Int J Clin Pharm       Date:  2011-04-07

3.  An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.

Authors:  Yiming Cheng; Liangang Liu; Yongjun Xue; Simon Zhou; Yan Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-06-03       Impact factor: 2.441

4.  Gastrointestinal tuberculosis is not associated with proton pump inhibitors: a retrospective cohort study.

Authors:  Kyoung Sup Hong; Seung Joo Kang; Jong Kyoung Choi; Ju Han Kim; Heewon Seo; Suehyun Lee; Jae-Woo Jung; Hye-Ryun Kang; Sang-Heon Cho; Joo Sung Kim
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

Review 5.  The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors.

Authors:  Helen F Boardman; Gordon Heeley
Journal:  Int J Clin Pharm       Date:  2015-06-23

6.  Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy-a proof of concept analysis.

Authors:  Jeffery D Kent; Robert J Holt; Donald Jung; George F Tidmarsh; Amy Y Grahn; Julie Ball; David A Peura
Journal:  J Drug Assess       Date:  2014-02-17

Review 7.  The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.

Authors:  David A Johnson; Philip O Katz; David Armstrong; Henry Cohen; Brendan C Delaney; Colin W Howden; Peter Katelaris; Radu I Tutuian; Donald O Castell
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

8.  Repeated Famotidine Administration Results in a Diminished Effect on Intragastric pH in Dogs.

Authors:  M K Tolbert; A Graham; A Odunayo; J Price; J M Steiner; K Newkirk; S Hecht
Journal:  J Vet Intern Med       Date:  2016-12-01       Impact factor: 3.333

Review 9.  Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition.

Authors:  Moon Kyung Joo; Chan Hyuk Park; Joon Sung Kim; Jae Myung Park; Ji Yong Ahn; Bong Eun Lee; Jeong Hoon Lee; Hyo-Joon Yang; Yu Kyung Cho; Chang Seok Bang; Beom Jin Kim; Hye-Kyung Jung; Byung-Wook Kim; Yong Chan Lee
Journal:  Gut Liver       Date:  2020-11-15       Impact factor: 4.519

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.